If your email program has trouble displaying this email, view as a webpage.

Virtual Town Hall Series - Test Development and Validation During Public Health Emergencies -- Monkeypox (mpox) and COVID-19

On Wednesday, February 15, from 12:05 to 1 p.m. ET, the U.S. Food and Drug Administration (FDA) will host the next session of the virtual town hall series on test development and validation during public health emergencies. The topic will be on monkeypox (mpox) and COVID-19. No registration required.

Panelists include:

• Timothy Stenzel, M.D., Ph.D., Director of the Office of In Vitro Diagnostics
• Toby Lowe, Associate Director for Regulatory Programs, Office of In Vitro Diagnostics
• Kristian Roth, Ph.D., Deputy Director of the Division of Microbiology Devices, Office of In Vitro Diagnostics
• Noel Gerald, Ph.D., Branch Chief for Bacterial Respiratory and Medical Countermeasures, Office of In Vitro Diagnostics

There will be an opportunity to ask questions live on the call, and questions may also be submitted in advance by emailing CDRHWebinars@fda.hhs.gov.

• Submit questions by 12 p.m. ET on Monday, February 13, 2023.
• In the subject line of the email, type “Questions for the Virtual Town Hall Series - Test Development and Validation During Public Health Emergencies”. Please specify in your email if your question is for monkeypox (mpox), COVID-19, or both.

If you cannot attend the live virtual town hall, the recording and transcript will be available at CDRH Learn.

Questions?

• See the FAQs on Testing for Monkeypox.
• See the FAQs on Testing for SARS-CoV-2.
• For specific questions about monkeypox (mpox) diagnostic development, contact MPXDx@fda.hhs.gov.
• For specific questions about COVID-19 diagnostic development, contact COVID19DX@fda.hhs.gov.

For general questions about this town hall series, contact Division of Industry and Consumer Education.